Angel Foster, MD, highlights the importance of telehealth for abortion care

News
Video

In the wake of tightening abortion laws, telemedicine and advance provision of abortion pills are emerging as essential, safe, and accessible solutions for reproductive health care.

In a recent interview with Contemporary OB/GYN, Angel Foster, MD, founder of The Massachusetts Abortion Access Project (MAP), addressed the growing fear and challenges patients face when seeking abortion care in the United States following the Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization, which overturned Roe v. Wade.

Foster noted that roughly one-third of women and girls of reproductive age now live in states that have implemented near-total abortion bans or first-trimester restrictions. This legal environment has led to heightened anxiety not only for those facing unintended pregnancies but also for individuals with wanted pregnancies that develop complications such as miscarriage or stillbirth. The fear and uncertainty are especially acute in states with aggressive anti-abortion legislation.

Despite these legal setbacks, Foster highlighted the resilience and innovation in abortion care delivery. One key advancement is the expansion of medication abortion via telemedicine. Shield laws in supportive states protect providers and patients, enabling access to abortion pills regardless of geographic restrictions. Foster emphasized the importance of what she calls “Mife in all 50,” a reference to the availability of mifepristone, a medication used for abortion, across the United States through telehealth services.

Telehealth now accounts for about 1 in 4 abortions nationwide, and it has become especially vital in states with near-total bans. Many patients are opting for at-home care over traveling long distances to brick-and-mortar clinics. According to Foster, telemedicine abortion is not only medically safe and effective but also highly acceptable to patients.

To further enhance access, services such as the MAP offer affordable care using a pay-what-you-can model, starting at just $5. Another forward-thinking strategy is "advance provision," where individuals obtain abortion pills before they are pregnant, ensuring timely access if the need arises. Currently, 1% to 5% of MAP’s monthly patients request pills for potential future use.

Looking ahead, Foster stressed the need for proactive legislation to safeguard abortion rights and to defend providers facing lawsuits. She asserts that medication abortion pills are here to stay, and even if legal restrictions tighten, alternative avenues—such as international providers and community distribution networks—will continue to meet patient needs. The reproductive healthcare landscape is evolving rapidly in response to legal pressures, and innovation remains key to maintaining access.

No relevant disclosures.

Reference

Welcome to the MAP. Cambridge Reproductive Health Consultants. Accessed July 30, 2025. https://www.crhcmap.org/.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Thomas McElrath, MD, PhD, highlights limitations of current preeclampsia guidelines | Image Credit: physiciandirectory.brighamandwomens.org.
Ousseny Zerbo, PhD, highlights benefits of influenza vaccination during pregnancy | Image Credit: divisionofresearch.kaiserpermanente.org.
Michael Ussher, PhD, highlights the benefits of vaping over smoking in pregnancy | Image Credit: sgul.ac.uk.
Eran Bornstein, MD, highlights early signs of preeclampsia clinicians need to know | Image Credit: northwell.edu.
Eran Bornstein, MD explains the need for first trimester preeclampsia screening | Image Credit: northwell.edu.
Veerle Bergink, MD, PhD, highlights familial links of postpartum psychosis | Image Credit: profiles.mountsinai.org.
Ivie Odiase, MD
Amy Valent DO, MCR, highlights new tech for prenatal diabetes management | Image Credit: linkedin.com.
Johanna Finkle, MD, weight loss specialist, OB/GYN, The University of Kansas Health System.
Laxmi Gannu, MD, notes PPD screening gaps and adverse outcomes | Image Credit: linkedin.com.
Related Content
© 2025 MJH Life Sciences

All rights reserved.